Trial Profile
Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Aminopterin (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Sanofi Genzyme
- 16 Sep 2018 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 17 Sep 2005 New trial record.